Results 91 to 100 of about 72,428 (200)
Recent Advances in Isatin–Thiazole Hybrids: Synthesis, Structural Design, and Biological Application
Chemistry &Biodiversity, EarlyView.ABSTRACT Isatin–thiazole hybrids are considered privileged chemical scaffolds due to their broad spectrum of pharmacological properties, making them attractive candidates for drug development. As a result, isatin–thiazole derivatives have emerged as a prominent class of hybrid heterocycles and have been the focus of extensive research in recent years ...
Isadora M. G. Andrade +4 more
wiley +1 more source
International Journal of Nanomedicine, 2016 Shaomei Yang,1 Bo Zhang,1 Xiaowei Gong,2 Tianqi Wang,1 Yongjun Liu,1 Na Zhang1 1Department of Pharmaceutics, College of Pharmacy, Shandong University, 2Shandong Provincial Key Laboratory of Neuroprotective Drug, Jinan, Shandong Province, People’s ...
Yang S +5 more
doaj
Biocompatible Chemistry: A Plug‐and‐Play Toolbox for Chemical Biology Research
ChemBioChem, EarlyView.The “plug‐and‐play” nature of biocompatible chemistry makes it a powerful toolbox for investigating complicated biological systems and producing drug leads for clinical usages. This review summarizes the commonly used biocompatible reactions and the recent advances of their representative applications in chemical biology research, thus highlighting the
Adam R. Lovato, Zeng Lin, Qingfei Zheng
wiley +1 more source
Cell Death and Disease, 2020 Increasing evidence supports that ferroptosis plays an important role in tumor growth inhibition. Sorafenib, originally identified as an inhibitor of multiple oncogenic kinases, has been shown to induce ferroptosis in hepatocellular carcinoma (HCC ...
Qiujie Wang +6 more
semanticscholar +1 more source
Gankyrin‐Protein Interactions in GI Cancers: A Novel Target of New Therapeutics
Chronic Diseases and Translational Medicine, EarlyView.ABSTRACT Gankyrin (PSMD10) is a 25 kDa oncogenic protein and regulatory subunit of the 26S proteasome, characterized by a sevenfold ankyrin repeat domain. Gankyrin is overexpressed in various malignancies, particularly gastrointestinal (GI) cancers. Gankyrin contributes to tumorigenesis by modulating key signaling pathways and engaging in oncogenic ...
Shuang Li +4 more
wiley +1 more source
Nanomaterial‐Based Precision Medicine for Breast Cancer Diagnosis and Treatment
ChemNanoMat, EarlyView.This research emphasizes the use of targeted precision medicine in the treatment of breast cancer. Through the integration of diagnosis and therapeutic delivery, nanocarriers are designed to selectively target cancer cells, preserving healthy tissue, thereby improving treatment effectiveness and reducing side effects.
Tanaka Ndongwe +8 more
wiley +1 more source
Molecular Cancer, 2020 Background and aims Accumulating evidence suggests that the primary and acquired resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple molecular, cellular, and microenvironmental mechanisms. Understanding these mechanisms will
Junjie Xu +12 more
semanticscholar +1 more source
Cancer Medicine, 2020 Sorafenib has become the only FDA‐approved first‐line therapy for advanced hepatocellular carcinoma (HCC) for more than 10 years, but there is still no validated predictive or prognostic marker.
Pusen Wang +6 more
doaj +1 more source
Cancer Cell International, 2019 Background Effective therapy for hepatocellular carcinoma (HCC) is currently an imperative issue, and sorafenib is a first-line drug for the treatment of HCC. However, the clinical benefit of sorafenib is often impaired by drug resistance.
Jie Song, Wei Zhao, Chang Lu, Xue Shao
doaj +1 more source
International Journal of Cancer, EarlyView.Abstract Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge.
Longtao Zhao +6 more
wiley +1 more source